Abstract 10P
Background
Multi-gene expression tests have been widely accepted as risk-prediction tools in early-stage HR-positive and HER2-negative (HR+/HER2-) breast cancer (EBC) after surgery. This study compared the performance of the 28-gene panel that developed from the Asian breast cancer population with the 70-gene panel in Chinese women with EBC.
Methods
Pts with EBC, previously undergone 70-gene testing after primary surgery from Jan 2019 to Oct 2022 were enrolled. FFPE of primary breast tumors were collected for 28-gene testing. Clinicopathological risk factors such as diagnosed age ≤40y, ≥T2, N1, LVI positive, grade III, Ki-67≥ 20% were included in the final analyses. Pts with clinicopathological risk factors ≥2 were clinical high-risk (n=48); others were low-risk (n=51).
Results
A total of 99 Chinese pts with EBC (pT1-2N0-1 or pT3N0M0) were enrolled in this study, with a median diagnosed age of 52 years (29-74 years). The median follow-up period was 38 months, and the last follow-up date was June 20, 2023. Two pts were lost to follow-up, but none recurred or died. The 28-gene and 70-gene panels detected high-risk pts (26% vs. 34%) and low-risk (73% vs. 65%), respectively. The overall agreement of the two tests was 72% (71/99). In addition, the 28-gene panel showed higher consistency with clinical-risk prediction than the 70-gene panel (Kappa: 0.51 vs. 0.39). Among them, the consistency of the 28-gene panel and 70-gene panel with the low clinical-risk prediction was 98% (50/51) and 84% (43/51), respectively; the high-risk prediction was 47% (25/48) and 54% (26/48), respectively. Table: 10P
Risk prediction comparison of 28-gene and 70-gene panels
| Characteristic | 28-gene (%) | Kappa | 70-gene (%) | Kappa | |||
| High-risk | Low-risk | High-risk | Low-risk | ||||
| Clinical | High-risk | 25(25) | 23(23) | 0.51 | 26(26) | 22(22) | 0.39 |
| Low-risk | 1(1) | 50(51) | P<0.001 | 8(8) | 43(43) | P<0.001 | |
| Total | 26(26) | 73(74) | 99(100) | 34(34) | 65(66) | 99(100) |
Conclusions
The performance of the 28-gene panel in risk prediction of EBC was comparable with the 70-gene panel. The 28-gene panel could identify a more low-risk population in Chinese breast cancer pts. An enlarged sample size and longer follow-up for clinical outcomes will further confirm our conclusions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Key Research and Development Program of China (2019YFE0196500).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract